Bio-Gate AG: directors' dealings · Germany · BaFin

About Bio-Gate AG

Bio-Gate AG is a German healthcare technology company listed on Xetra/Frankfurt (DAX/MDAX/SDAX), operating as a niche specialist at the intersection of human health, animal health, and surface hygiene. Headquartered in Germany, with operating sites in Nuremberg and Bremen, the company develops and commercializes antimicrobial and antiviral solutions designed to improve safety in hygiene-sensitive environments. Its business model is based on the monetization of proprietary technologies applied to materials, products, and surfaces, rather than on the sale of conventional pharmaceuticals. Founded in the early 2000s, Bio-Gate has built its expertise around two core technology platforms. The first is HyProtect™, an ultrathin plasma coating designed to reduce bacterial colonization on medical implants, particularly in orthopaedics. The second is MicroSilver BG™, an antimicrobial and antiviral additive that can be integrated into a wide range of materials and formulations. This technological base allows the group to address several end markets: medical devices, dermatological care and wound management, veterinary products, and industrial/consumer hygiene applications. From a competitive standpoint, Bio-Gate is differentiated less by scale than by specialization, intellectual property, and its ability to industrialize niche solutions with added value. The company collaborates with universities and research institutes and operates an independent microbiological testing subsidiary, QualityLabs BT GmbH, which strengthens the scientific credibility of its development work. In parallel, Bio-Gate is expanding veterinary products through VetInnovations, with increasing commercial reach in Europe and North America. Recent disclosures point to gradual operational improvement. In 2025, the company reported an expanded North American presence in veterinary care, while clinical data supported the commercialization of medical CBD-based care products. In December 2024, Bio-Gate announced a key step toward serial production of HyProtect™-coated orthopaedic implants, with a clinical study underway for CE approval. For fiscal 2025, the company reported in April 2026 revenue of EUR 7.4 million and a narrower net loss, indicating that operating leverage is developing, albeit from a still modest base. For investors, Bio-Gate remains a German micro/small-cap innovation story exposed to attractive end markets, but still in the scaling phase.